Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate

Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

vaccine up close
• Source: Alamy

Clive Dix is used to sorting out complicated challenges. He has founded and run several biotechs in his time and has a broad knowledge of the scientific and commercial landscapes of a variety of therapeutic areas. But he really found himself in the eye of the storm when in 2020 he was appointed deputy chair of the UK’s Vaccine Taskforce to help lead efforts to find and manufacture a coronavirus vaccine. The government established the Taskforce in March 2020, and it reported directly to the Business Secretary. Dame Kate Bingham was appointed the Taskforce’s chair in May 2020, and Dix later stepped up to lead as interim chair for a period in early 2021 after she stood down.

Dix, who holds a degree and a PhD in pharmacology, is currently executive chair of C4X Discovery Holdings plc,...

More from COVID-19

More from In Vivo